Embedding patient centricity Understanding the role of real-world evidence in global market access strategies. Copyright 2014 Quintiles
|
|
- Belinda Owens
- 8 years ago
- Views:
Transcription
1 Embedding patient centricity Understanding the role of real-world evidence in global market access strategies Copyright 2014 Quintiles
2 Agenda Introduction Real-world evidence: Increasing access to innovative treatments Louise Parmenter The evolution of the patient voice: View point of an ex-regulator Stella Blackburn Q&A These materials have been prepared solely for educational purposes to contribute to the understanding of patient centricity and real-world evidence. Quintiles makes no representations or warranties about the accuracy or suitability of any information in the materials; all such content is provided to participants on an as is basis. QUINTILES HEREBY DISCLAIMS ALL WARRANTIES REGARDING THE CONTENTS OF THESE MATERIALS, INCLUDING WITHOUT LIMITATION, ALL WARRANTIES OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY, AND FITNESS FOR A PARTICULAR PURPOSE 2
3 Today s speakers Louise Parmenter, Global Head of Operations, Epidemiology and Outcomes Research, Real-World and Late Phase at Quintiles Specialist in real-world and late phase research with 22 years of related global operational and strategic experience. She is currently responsible for a team of epidemiologists and outcomes researchers primarily based in the United States with growing teams in Europe and Asia. The team s focus areas include safety, comparative effectiveness, design and implementation of Risk Evaluation and Mitigation Strategies (REMS), outcomes research and methods development. In this capacity, Dr. Parmenter is responsible for study design, scientific oversight and study publication. Stella Blackburn, Vice President, Global Head of Risk Management, Real-World and Late Phase Research at Quintiles Leads risk management efforts in North America, Europe and Asia-Pacific for the Quintiles real-world and late phase research group. In her role, Dr. Blackburn develops multidisciplinary benefit risk management services, reviews and assists customers with interpretation of pharmacovigilance legislation, and ensures compliance with regulations and best practices in the conduct of pharmacovigilance and risk management activities for the company s real-world and late phase research efforts. With more than two decades of experience in the pharmacovigilance and pharmacoepidemiology fields, Dr. Blackburn joined Quintiles from the European Medicines Agency (EMA) where she served for more than 16 years in various roles, most recently as the EMA Risk Management Development and Scientific Lead 3
4 Real-world evidence increasing access to innovative treatments 4
5 As a form of practice it seeks to focus medical attention on the individual patient s needs and concerns rather than the doctor s. Defining Patient-Centered Medicine Bard, Charles L, Defining Patient Centered Medicine : New England Journal of Medicine ;9 5
6 Benefits of patient-centered approaches to healthcare Improvement Physician satisfaction Patients emotional state Medication adherence Patient satisfaction and empowerment Malpractice complaints Consultation time Symptom severity Healthcare resource use Healthcare costs Reduction HUDON, C., FORTIN, M., HAGGERTY, J. L., LAMBERT, M. & POITRAS, M.-E Measuring Patients Perceptions of Patient-Centered Care: A Systematic Review of Tools for Family Medicine. Annals of Family Medicine, 9,
7 Examples of decision-makers promoting patient-centered approaches Patient-Centered Outcomes Research Institute (PCORI) European Medicines Agency 7
8 PCORI s research project agenda Research shall be designed, as appropriate, to take into account the potential for differences in the effectiveness of health care treatments, services, and items as used with various subpopulations, such as racial and ethnic minorities, women, age, and groups of individuals with different comorbidities, genetic and molecular sub-types, or quality of life preferences and include members of such subpopulations as subjects in the research as feasible and appropriate. US Patient Protection and Affordable Care Act US Social Security Administration Sec [42 U.S.C. 1320e] Accessed 19 April
9 European Medicines Agency adaptive pathways to patients (formally Adaptive Licensing ) March 2014: Adaptive Licensing December 2014: Adaptive Pathways Regulators, companies, Health Technology Assessment bodies (HTAs) and patient representatives Explore ways to optimise development pathways and potentially accelerate patients access to medicines. This faster access may be achieved by shorter time to approval and/or reimbursement decision for targeted groups of patients. Adaptive pathways to patients: report on the initial experience of the pilot project December EMA/758619/
10 So how does a patient centered approach impact the role of real-world evidence in global market access strategies? 10
11 A paradigm shift in thinking Market Access Patient- Centric Thinking Patient Access John Glasspool Sep 20, 2013 Pharmaceutical Executive. Market Access is Dead: Patient Access is the New Prescription for Healthcare Marketing 11
12 A Paradigm Shift in Thinking Market Access Patient- Centric Thinking Patient Access John Glasspool Sep 20, 2013 Pharmaceutical Executive. Market Access is Dead: Patient Access is the New Prescription for Healthcare Marketing 12
13 Drives a new patient-centered approach Research and Development License Market Access Commercial availability Commercial Ethical sales 13
14 Drives a new patient-centered approach Research and Development Patient Outcomes Market Access Patient Outcomes Commercial Patient Outcomes 14
15 Pfizer Exubera First U.S. inhaled insulin for diabetes FDA approval in January 2006 Anticipated blockbuster Withdrawn from the market in October 2007 Lack of consumer demand This amazing science, incredible engineering, and true breakthrough frankly did not resonate with patients and their lifestyle. We realized we hadn't asked all the right questions of the right patients at the right time, and yet we continued pushing forward. Pfizer s Chief Medical Officer Pfizer: Putting The Patient At The Center Of Its Drug Development Universe. Life Science Leader December 24,
16 Pfizer Xeljanz (tofacitinib) Indicated for rheumatoid arthritis FDA approval in November 2012 A year later, the FDA approved a supplemental new drug application (snda) including additional patientreported outcomes data. Eight domains of the 36 item Medical Outcomes Study Short- Form Health Survey (SF-36) now appear in the label. We worked to include things that are not usually part of a clinical trial. That's a soup-tonuts example of listening to patients about what's important to them, including it in clinical trials, collecting and analyzing the data, and then sharing it back with the patient community Pfizer s Chief Medical Officer Pfizer: Putting The Patient At The Center Of Its Drug Development Universe. Lifescience Leader December 24,
17 Lilly to use real-world data in diabetes collaboration Lilly is to use data collected in an everyday setting as part of a collaboration with the T1D Exchange to research new ways to improve care for people with type 1 diabetes. PM Live April
18 10 steps towards patient access Toward Patient-Centered Drug Development in Oncology. Ethan Basch New England Journal of Medicine August :5 18
19 Key steps towards patient access Step Appoint senior executives to lead patient engagement efforts and focus all teams on patient outcomes Use real-world studies to establish burden of disease, resource utilization, population, subpopulation, and individual patient characteristics, and treatment pathways Timing Throughout drug development Throughout drug development Discuss plans for measuring and analyzing patient-centered outcomes at structured meetings between drug-development team, regulatory agency and where possible, payers Throughout drug development Engage patients representative of the target population Generate evidence in patients representative of target population likely to use the product Throughout drug development Throughout drug development Adapted from Toward Patient-Centered Drug Development in Oncology. Ethan Basch New England Journal of Medicine August :5 19
20 Key steps towards patient access Step Identify patient-centered outcomes (symptom, functional, and other outcomes affected by a disease or product and important to patients) through direct patient feedback Develop or select measures to evaluate outcomes using established qualitative and quantitative methods Include PRO and other patient-centered measures in pivotal trials, with protocol-specified plans for statistical analysis as well as minimizing and handling missing data Include PROs in drug labels to help patients and providers with decision making Evaluate product use in the real-world: safety & effectiveness; compliance, adherence, persistence; treatment satisfaction using robust research methods Timing Before pivotal trials Before pivotal trials Pivotal trials Regulatory review Post-launch Adapted from Toward Patient-Centered Drug Development in Oncology. Ethan Basch New England Journal of Medicine August :5 20
21 The evolution of the patient voice a viewpoint from an ex-regulator 21
22 L état, c est moi 22
23 Key stakeholders in drug development Biopharma Doctors Regulators Patients Drug Development Payers 23
24 Patient needs Medicines to meet unmet medical needs Affordable medicines Medicines with predictable outcomes Medicines with fewer side effects 24
25 Patient needs Medicines to meet unmet medical needs Affordable medicines Medicines with predictable outcomes Medicines with fewer side effects But do we really know what patients want? 25
26 Key milestones of EMA interactions with patients and consumers Slide from EMA website accessed 20/04/
27 Current representation on PCWP Age Platform Europe Alzheimer Europe European AIDS treatment group European Cancer Patient Coalition European Consumers Organisation European Federation of Allergy and Airways Diseases Patients Associations European Federation of Neurological Associations European Heart Network European Institute of Women s Health European Multiple Scelerosis Platform European Organisation for Rare Diseases European Patients Forum European Prostate Cancer Coalition European Public Health Alliance Health Action International Europe International Alliance of Patients Organisations International Diabetes Federation European Region International Patient Organisation for Primary Immunodeficiencies Patients Network for Medical Research and Health 27
28 Involvement of patients at the EMA Part of the EMA Management Board (2 members) Inclusion in scientific committees as members COMP 3 members PDCO 3 members CHMP CAT 2 members PRAC 1 member 28
29 Involvement of patients at the EMA Contributions on disease and product-specific questions Scientific Advice Working Party (SAWP) Scientific Advisory Groups (SAG) Consultation on guidelines and policies Review of documents destined for the public Dissemination of information Participation in workshops, networks and research projects 29
30 The patients and representatives in the room, in their statements, defended the position that at that late stage of the disease even small effects providing longer independent use of arms and hands, or preserving the ability to feed and drink from a cup on their own, would represent a significant and important effect. Taken from EPAR for Translarna 30
31 Key contributions from patients What benefits of a medicine are important for patients? What level of risk is acceptable? What level of risk minimisation is acceptable? Which medicines/treatments should be funded? 31
32 Challenges Are patient representatives really representative? Who owns patient data? 32
33 WP4: The PROTECT Pregnancy Study New tools for data collection from consumers The PROTECT project has received support from the Innovative Medicines Initiative Joint Undertaking ( under Grant Agreement n , resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/ ) and EFPIA companies in kind contribution.
34 New tools for data collection from consumers An exploratory study of self-reported medication use in pregnant women and pregnancy outcomes Objectives To assess the extent to which data collected directly from pregnant women via the Internet and IVRS provides information on medication use and other potential risk factors throughout pregnancy, and is suitable for research purposes 34
35 An exploratory study of self-reported medication use in pregnant women and pregnancy outcomes Questions: Can we get data earlier in pregnancy than traditional routes? How consistently and for how long will women provide the data requested? How representative are the women? How important are data not captured by EHR or pharmacy databases? Is the information of sufficient quality to be used for pharmacovigilance? 35
36 Data collection flow IVRS Baseline questionnaire 2 weekly Web Baseline questionnaire Follow up Follow up Follow up Follow up Pregnancy outcome Satisfaction Q Follow up Follow up 4 weekly Discontinuation Questionnaire 36
37 Data collected Baseline Demographics Lifestyle and risk factors Pregnancy-related information Medications, supplements, vaccinations, contraception, medical/cosmetic procedures, herbals, others Follow-up Change to expected date of delivery Changes to previous medications New problems and medications Vaccinations and others End of study Pregnancy outcomes: live birth, miscarriage/still birth, termination, ectopic pregnancy Birth defects Satisfaction questions 37
38 Work package 4 - Study population 4 countries: Denmark Poland The Netherlands United Kingdom 2065 women provided data Self identified as pregnant Recruited directly, without intervention of HCP 38
39 Data which may not be found elsewhere DK % (n) NL % (n) PL % (n) UK % (n) All % (n) Stopped medications when pregnant 15 (95) 11 (51) 11 (27) 18 (126) 14 (299) Stopped doctor s prescribed medications 5 (31) 4 (19) 5 (11) 6 (39) 5 (100) Used medications from other people 0.3 (2) 1 (3) 0.4 (1) 1 (5) 0.5 (11) Had vaccinations 14 (92) 4 (19) 3 (6) 49 (345) 22 (462) Stopped smoking 17 (106) 14 (68) 19 (45) 16 (114) 16 (333) Reported illicit drug use 1 (6) 0.4 (2) 0.4 (1) 1 (8) 1 (17) 39
40 Conclusion It is possible to recruit women early in pregnancy before they may have consulted HCPs Direct to consumer studies offer important benefits in collecting certain data not found in EHR 40
41 Conclusion Biopharma Regulators Doctors Patients Payers 41
42 Audience questions 42
II. AREA OF INVOLVEMENT OF PATIENTS AND CONSUMERS IN EMEA ACTIVITIES
European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use MINUTES OF THE EIGHTH MEETING OF THE EMEA HUMAN SCIENTIFIC COMMITTEES WORKING PARTY WITH PATIENTS' AND CONSUMERS' ORGANISATIONS
More informationWhat Lies Ahead? Trends to Watch: Health Care Product Development in North America
What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the
More informationBig Data for Patients (BD4P) Stakeholder Engagement Plan
Big Data for Patients (BD4P) Stakeholder Engagement Plan Index I. BD4P Program Background a. Goals and Objectives II. Participation a. How will stakeholders be engaged? i. Stakeholders ii. Workgroups III.
More informationBig Data for Patients (BD4P) Program Overview
Big Data for Patients (BD4P) Program Overview [Updated August 5, 2015] Proposal: Big Data for Patients (BD4P) Training Program Page 1 Background The new and emerging field of data science ( Big Data )
More informationThe Role of the Patient/Consumer in Establishing a Dynamic Clinical Research Continuum:
The National Working Group on Evidence-Based Health Care The Role of the Patient/Consumer in Establishing a Dynamic Clinical Research Continuum: Models of Patient/Consumer Inclusion August 2008 The Working
More informationThe Role of Regional Medical Advisor (RMA)-Field Medical. Dr. Aju Abraham Varghese Pfizer India. Feb 22 nd 2014
The Role of Regional Medical Advisor (RMA)-Field Medical Dr. Aju Abraham Varghese Pfizer India Feb 22 nd 2014 Disclaimer The opinions expressed in this presentation are solely those of the presenter and
More informationIntroduction and Invitation for Public Comment
2 of 22 Introduction and Invitation for Public Comment The Patient-Centered Outcomes Research Institute (PCORI) is an independent, non-profit health research organization. Its mission is to fund research
More informationEnabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV
Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Maria Isaac, MASc, MD, PhD, MFPM, Psychiatrist Senior Scientific Officer Institute
More informationEMA Update Clinical Trials
EMA Update Clinical Trials Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency 16 October 2012 An agency of the European Union Disclaimer The views presented in this presentation/these
More informationPEDIATRIC MEDICINES: GLOBAL MARKETS
PEDIATRIC MEDICINES: GLOBAL MARKETS PHM170A October 2014 Dr. Cheryl Lee Barton Project Analyst ISBN: 1-56965-971-0 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationMethodology for Safety Surveillance of Adverse Events Following Vaccination During Pregnancy
Methodology for Safety Surveillance of Adverse Events Following Vaccination During Pregnancy C. Jouquelet-Royer September 2012 Fondation Merieux NAME OF PRESENTATION 1 Presentation Outline Background Company
More informationThe registry of the future: Leveraging EHR and patient data to drive better outcomes
The registry of the future: Leveraging EHR and patient data to drive better outcomes Brian J. Kelly, M.D. President, Payer and Provider Solutions, Quintiles Jason Colquitt, VP, IT, Head of RWLPR IT, Global
More informationImpact of Clinical Education as Part of a Multichannel Sales Strategy
Impact of Clinical Education as Part of a Multichannel Sales Strategy June 13, 2012 Copyright 2012 Quintiles Topics Impact of Clinical Education as part of a Multichannel Sales Strategy -Introduction to
More informationActionable Insights into Health Policy, Practice and Outcomes Through Research and Big Data - with a Spotlight on Oncology
Actionable Insights into Health Policy, Practice and Outcomes Through Research and Big Data - with a Spotlight on Oncology Attend the Virtual Meeting in HE-Xpo Wednesday, Feb. 18, 2015 Session One: 9:30
More informationHow To Weigh Data From A Study
PRINCIPLES ON RESPONSIBLE SHARING OF TRUTHFUL AND NON-MISLEADING INFORMATION ABOUT MEDICINES WITH HEALTH CARE PROFESSIONALS AND PAYERS INTRODUCTION In the era of data-driven medicine, where all parties
More informationHTA and Post-Launch Studies
EXPLORING THE FUTURE OF RE FOR DRUGS IN EUROPE ELEMENTS AFFECTING THE FUTURE OF RE IN EUROPE? Baseline factors Payers continue to face austerity pressures Decision making by Payer / HTA bodies remains
More informationA competency framework for all prescribers updated draft for consultation
A competency framework for all prescribers updated draft for consultation Consultation closes 15 April 2016 Contents 1 Introduction... 3 2 Uses of the framework... 4 3 Scope of the competency framework...
More informationBig Data in Health Sciences An India Prospective
Big Data in Health Sciences An India Prospective Government Industry Dialogue 24 th Nov 2013 1 Views presented are Individual views only 2 Healthcare Ecosystem Stakeholders and Influencers Drugs and Devices
More informationEMA and Progressive Multifocal Leukoencephalopathy.
EMA and Progressive Multifocal Leukoencephalopathy. ENCePP Plenary, London 23 November 2011 Presented by: Henry Fitt Head of Coordination & Networking, Pharmacovigilance & Risk Management An agency of
More informationSeminario SSFA. New Guideline on Good Pharmacovigilance Practice (GVP) Fare clic per modificare lo stile del sottotitolo dello schema
Seminario SSFA New Guideline on Good Pharmacovigilance Practice (GVP) Pharmacovigilance Systems and their Quality Systems Milano, 20th April 2012 GIULIA M. VALSECCHI The proposed GVP - Module 1 Guidance
More informationThe EFPIA Disclosure Code: Your Questions Answered
The EFPIA Disclosure Code: Your Questions Answered Working together: why do the pharmaceutical industry and healthcare professionals work together? 1 Why does industry pay health professionals to provide
More informationSetting Standards in Public Health Training. The Australian Experience Asia-Pacific Academic consortium for PH Accreditation in PH Education
Setting Standards in Public Health Training The Australian Experience Asia-Pacific Academic consortium for PH Accreditation in PH Education Drivers Kerr White 1986 Review of research and educational requirements
More informationPrescription Drug Information for Patients: History
Prescription Drug Information for Patients: History 1500s: Ethical Statutes of Royal College of Physicians Let no physician teach the people about medicines or even tell them the names of the medicines,
More informationComments on the 21 st Century Cures: Digital Health Care
Comments on the 21 st Century Cures: Digital Health Care July 22, 2014 The Pharmaceutical Research and Manufacturers of America (PhRMA) appreciates the opportunity to provide input to the House Energy
More informationSafety Risk Management Company Perspective
Safety Risk Management Company Perspective Akihisa Harada, MD, Ph.D VP, Development Japan Pfizer Japan Inc. R&D Head Club Agenda REMS in FDAAA Safety Risk Management throughout a Drug s Lifecycle Risk
More informationCPRD Clinical Practice Research Datalink john.parkinson@cprd.com Scotland Meeting May 2012
CPRD Clinical Practice Research Datalink john.parkinson@cprd.com Scotland Meeting May 2012 Computational Biochemist PhD Liverpool Pharma Healthcare Food Advertising JWT Healthcare Medical Education UoD
More informationStrategy and pilot phase for patient registries
Strategy and pilot phase for patient registries Draft still under discussion Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015 Xavier Kurz, Head of Monitoring
More informationThe European regulatory system for medicines and the European Medicines Agency
The European regulatory system for medicines and the European Medicines Agency A consistent approach to medicines regulation across the European Union An agency of the European Union This booklet is intended
More informationManchester Pharmacy School. www.manchester.ac.uk/pharmacy
Manchester Pharmacy School Postgraduate study from Continuous Professional Development (CPD), Certificate, Diploma to Masters (MSc) with flexible, modular learning. The University of Manchester has a proud
More informationOverview of the EHR4CR project Electronic Health Record systems for Clinical Research
Overview of the EHR4CR project Electronic Health Record systems for Clinical Research Dipak Kalra UCL on behalf of the EHR4CR Consortium ENCePP Plenary Meeting, 3rd May 2012, London The problem (as addressed
More informationClinical Communications Programs with Healthcare Professionals and Patients
A Multichannel Approach Clinical Communications Programs with Healthcare Professionals and Patients A Publicis Touchpoint Solutions White Paper Best Practices Series 2011 Publicis Touchpoint Solutions,
More informationHOT TOPICS IN IN HEALTH CARE REFORM
By Felicia Fuller Publications Manager, DAC Patient Recruitment Services The Patient Protection and Affordable Care Act (ACA), colloquially known as Obamacare, is in full effect and its impact is palpable
More informationEUROPEAN CITIZENS DIGITAL HEALTH LITERACY
Flash Eurobarometer EUROPEAN CITIZENS DIGITAL HEALTH LITERACY REPORT Fieldwork: September 2014 Publication: November 2014 This survey has been requested by the European Commission, Directorate-General
More informationEHR4CR ENABLING PROACTIVE RESEARCH
EHR4CR ENABLING PROACTIVE RESEARCH Neelam Patel Neelam Consulting Electronic Health Records for Clinical Research 76 Why change how I currently operate? To more visible to the clinical trial community
More informationDisease Management Identifications and Stratification Health Risk Assessment Level 1: Level 2: Level 3: Stratification
Disease Management UnitedHealthcare Disease Management (DM) programs are part of our innovative Care Management Program. Our Disease Management (DM) program is guided by the principles of the UnitedHealthcare
More informationIPROVE Innovation Partnership for a Roadmapon VaccinesinEurope
IPROVE Innovation Partnership for a Roadmapon VaccinesinEurope IPROVE IN BRIEF What is IPROVE? Whydo we need IPROVE? IPROVE in actions (How?) Partnership (Who?) WHAT An EU project (FP7) financed by the
More informationLeveraging Social Networks to Conduct Observational Research: A Paradigm Shift in Methodology. Presented by: Elisa Cascade, MediGuard/Quintiles
Leveraging Social Networks to Conduct Observational Research: A Paradigm Shift in Methodology Presented by: Elisa Cascade, MediGuard/Quintiles About Elisa Cascade, VP MediGuard/Quintiles Assisted in site
More informationEducation Surveys and Trends for 2014-17
3 June 2014 Education and Training Advisory Board 5 To consider Education surveys plan 2014-17 Issue 1 With the success of the National Training (NTS) there have been calls to expand the use of surveys
More informationPatient Reported Outcomes for Mental Health Services: Current Practice and Future Possibilities
Patient Reported Outcomes for Mental Health Services: Current Practice and Future Possibilities Arne Beck, PhD Kaiser Permanente Colorado Institute for Health Research September 12, 2012 DRAFT For Discussion
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/541760/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration
More informationEHR Databases and Their Role in Health & Innovation
8. New approaches to promoting innovation 8.4 Real-life data and learning from practice to advance innovation See Background Paper 8.4 (BP8_4Data.pdf) The costs of pharmaceutical R&D are high, with clinical
More informationI n t r o d u c t i o n
Preventing Alcohol and Drug Misuse in Young People: Adaptation and Testing of the Strengthening Families Programme 10-14 (SFP10-14) for use in the United Kingdom In 2006 Coombes et al produced a report
More informationSession 8: Bring Your Own Device (BYOD) - Application in Clinical Trials
Session 8: Bring Your Own Device (BYOD) - Application in Clinical Trials FIFTH ANNUAL PATIENT-REPORTED OUTCOME (PRO) CONSORTIUM WORKSHOP April 29-30, 2014 Silver Spring, MD Co-sponsored by Disclaimer The
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/541760/2011 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration with Member
More informationDIRECTOR OF PUBLIC HEALTH ROLE PROFILE
Appendix A DIRECTOR OF PUBLIC HEALTH ROLE PROFILE Title: Employing Organisation: Accountable to: Hours: Work base: Key Relationships Director of Public Health London Borough of Tower Hamlets Professionally
More informationDecember 23, 2010. Dr. David Blumenthal National Coordinator for Health Information Technology Department of Health and Human Services
December 23, 2010 Dr. David Blumenthal National Coordinator for Health Information Technology Department of Health and Human Services RE: Prioritized measurement concepts Dear Dr. Blumenthal: Thank you
More informationmhealth and ehealth: Understanding the future of cancer care
ECPC General Assembly 2016 Brussels, Belgium 3-5 June 2016 mhealth and ehealth: Understanding the future of cancer care Dee O Sullivan Director myhealthapps.net/patientview About PatientView UK-based research,
More informationAbt Associates Inc. Abt Associates Clinical Trials Comprehensive clinical research services
Abt Associates Inc. Abt Associates Clinical Trials Comprehensive clinical research services Providing a wide range of clinical research services Abt Associates Clinical Trials (AACT) is dedicated to providing
More informationMarket Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform
Market Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform By Joakim Steen Mikkelsen, Managing Healthcare Counselor, Embassy of
More informationThe PROTECT project. Introduction. Xavier Kurz Pharmacovigilance and Risk management Patient Health Protection Unit European Medicines Agency
The PROTECT project Introduction Xavier Kurz Pharmacovigilance and Risk management Patient Health Protection Unit European Medicines Agency Brookings Active Surveillance Implementation Council Meeting
More informationMSD Information Technology Global Innovation Center. Digitization and Health Information Transparency
MSD Information Technology Global Innovation Center Digitization and Health Information Transparency 10 February 2014 1 We are seeking energetic, forward thinking graduates to join our Information Technology
More informationDriving improved access to treatment via Europe and through national MS Societies
EMSP 2014 Spring Conference Driving improved access to treatment via Europe and through national MS Societies Christoph Thalheim EMSP Luiza Wieczynska PTSR 1 The pharmaceutical industry is suffering Expiring
More information(Resolutions, recommendations and opinions) RECOMMENDATIONS COUNCIL
3.7.2009 Official Journal of the European Union C 151/1 I (Resolutions, recommendations and opinions) RECOMMENDATIONS COUNCIL COUNCIL RECOMMENDATION of 9 June 2009 on patient safety, including the prevention
More informationIntroduction to Medication Management Systems, Inc. Comprehensive Medication Therapy Management Solutions
Introduction to Medication Management Systems, Inc. Comprehensive Medication Therapy Management Solutions Vision Medication Management Systems, Inc. (MMS) envisions a health care system in which all patients
More informationStakeholder Guide 2014 www.effectivehealthcare.ahrq.gov
Stakeholder Guide 2014 www.effectivehealthcare.ahrq.gov AHRQ Publication No. 14-EHC010-EF Replaces Publication No. 11-EHC069-EF February 2014 Effective Health Care Program Stakeholder Guide Contents Introduction...1
More informationSelf Care in New Zealand
Self Care in New Zealand A roadmap toward greater personal responsibility in managing health Prepared by the New Zealand Self Medication Industry Association. July 2009 What is Self Care? Self Care describes
More informationStreamline Your Radiology Workflow. With Radiology Information Systems (RIS) and EHR
Streamline Your Radiology Workflow With Radiology Information Systems (RIS) and EHR 2 Practicing medicine effectively requires transferring large amounts of information quickly, accurately, and securely.
More informationFDA Fast Track and Priority Review Programs
Order Code RS22814 February 21, 2008 FDA Fast Track and Priority Review Programs Summary Susan Thaul Specialist in Drug Safety and Effectiveness Domestic Social Policy Division By statutory requirements
More informationSkill Levels for Delivering High Quality Asthma and COPD Respiratory Care by Nurses in Primary Care
Skill Levels for Delivering High Quality Asthma and COPD Respiratory Care by Nurses in Primary Care September 2007 Revised December 2009, April 2014 Author: Ruth McArthur In conjunction with the PCRS-UK
More informationPatient Rights (Scotland) Bill. Roche Products Ltd
Patient Rights (Scotland) Bill Roche Products Ltd Roche is a leading manufacturer of innovative medicines, including in oncology, rheumatology and virology. We have expertise in a wide range of medical
More informationSubtitle D Patient-Centered Outcomes Research
Subtitle D Patient-Centered Outcomes Research SEC. 6301. PATIENT-CENTERED OUTCOMES RESEARCH. (a) IN GENERAL. Title XI of the Social Security Act (42 U.S.C. 1301 et seq.) is amended by adding at the end
More informationTHE EVOLVING BUSINESS MODEL FOR
THE EVOLVING BUSINESS MODEL FOR CLINICAL RESEARCH CHRIS BEARDMORE CHIEF EXECUTIVE OFFICER 6100 CENTER DRIVE, SUITE 600 LOS ANGELES, CA 90045 (424) 208-8866 CHRIS@TRMLLC.COM WWW.TRMLLC.COM Personalized
More informationEU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare
More informationRegulatory approval routes in the European System for Medicinal Products
Regulatory approval routes in the European System for Medicinal Products Cardiovascular Combination Pharmacotherapy Global Summit, Melbourne, 8 th May 2014 Presented by: Kevin Blake Human Medicines Research
More informationPUBLIC HEALTH LIMITED OPEN CALL SCHEME (LOCS) PHA202 RESEARCH BRIEFING
Introduction PUBLIC HEALTH LIMITED OPEN CALL SCHEME (LOCS) PHA202 RESEARCH BRIEFING Following publication of its new national health research strategy Best Research for Best Health (DH 2006a), the Department
More informationPatient-Centered Outcomes Research Definition Revision: Response to Public Input
Patient-Centered Outcomes Research Definition Revision: Response to Public Input CONSENSUS DEFINITION as of February 15, 2012 Patient-Centered Outcomes Research Working Definition Patient-Centered Outcomes
More informationMarket Access Consulting
Market Access Consulting Table of contents 01 Optimize your drug development journey 02 Overcome your unique challenges 03 Transform your results 04 Unlock your value story 05 Solutions for your success
More informationTHE ROLE OF HEALTH INFORMATION TECHNOLOGY IN PATIENT-CENTERED CARE COLLABORATION. 2012 Louisiana HIPAA & EHR Conference Presenter: Chris Williams
THE ROLE OF HEALTH INFORMATION TECHNOLOGY IN PATIENT-CENTERED CARE COLLABORATION 2012 Louisiana HIPAA & EHR Conference Presenter: Chris Williams Agenda Overview Impact of HIT on Patient-Centered Care (PCC)
More informationEUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES
EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES 24 OCTOBER 2011 INTRODUCTION 1. THE EUROPEAN CONTEXT Centres of expertise (CE) and European Reference
More informationPage 191 TITLE 21 FOOD AND DRUGS 355 1
Page 191 TITLE 21 FOOD AND DRUGS 355 1 APPEALS TAKEN PRIOR TO OCTOBER 10, 1962 Section 104(d)(3) of Pub. L. 87 781 made amendments to subsec. (h) of this section inapplicable to any appeal taken prior
More informationPROPOSED US MEDICARE RULING FOR USE OF DRUG CLAIMS INFORMATION FOR OUTCOMES RESEARCH, PROGRAM ANALYSIS & REPORTING AND PUBLIC FUNCTIONS
PROPOSED US MEDICARE RULING FOR USE OF DRUG CLAIMS INFORMATION FOR OUTCOMES RESEARCH, PROGRAM ANALYSIS & REPORTING AND PUBLIC FUNCTIONS The information listed below is Sections B of the proposed ruling
More informationWhat you should know about Data Quality. A guide for health and social care staff
What you should know about Data Quality A guide for health and social care staff Please note the scope of this document is to provide a broad overview of data quality issues around personal health information
More informationStrategic Consulting Services
Services 1 Leadership Team Mark Levonyak President mlevonyak@davaonc.com Mobile: 214.460.5051 Martin W. Lee, MD EVP, Clinical Trial Services mlee@davaonc.com Mobile: 952.373.1405 John Eckardt, MD Chief
More informationPatient Support Programs and Market Research Programs in Pharmacies: Managing Safety Information
Patient Support Programs and Market Research Programs in Pharmacies: Managing Safety Information Suzete Costa Pharm D, MPH Executive Director of the Centre for Health Evaluation & Research (CEFAR) National
More informationConsultation Response Medical profiling and online medicine: the ethics of 'personalised' healthcare in a consumer age Nuffield Council on Bioethics
Consultation Response Medical profiling and online medicine: the ethics of 'personalised' healthcare in a consumer age Nuffield Council on Bioethics Response by the Genetic Interest Group Question 1: Health
More informationThe new EU Clinical Trials Regulation How NHS research and patients will benefit
the voice of the NHS in Europe Briefing September 2014 Issue 19 The new EU Clinical Trials Regulation How NHS research and patients will benefit Who should read this briefing? This briefing will be of
More informationBioPharma Analytics Informing every move
Specialty Solutions Insight Decisions Providers Payors Direction Patients BioPharma Analytics Informing every move Achieve market success faster with evidence-based market intelligence Cardinal Health
More informationMy Big Data experience getting my feet wet in the puddle and still treading water 2 years later 28 th June 2013. Rob Walls Healthcare Data Analytics
My Big Data experience getting my feet wet in the puddle and still treading water 2 years later 28 th June 2013 Rob Walls Healthcare Data Analytics Abstract "Big Data" - Electronic Health Records (EHR)
More informationREGULATIONS FOR THE DEGREE OF MASTER OF CLINICAL PHARMACY (MClinPharm)
REGULATIONS FOR THE DEGREE OF MASTER OF CLINICAL PHARMACY (MClinPharm) (See also General Regulations) MCP1 Definition The degree of Master of Clinical Pharmacy (MClinPharm) is a postgraduate degree awarded
More informationElements for optimising Orphan drug development industry perspective
Elements for optimising Orphan drug development industry perspective IRDiRC Conference, Dublin, 17 April 2013 Wills Hughes-Wilson, Vice President External Affairs, Chief Patient Access Officer, Sobi With
More informationRegulatory Writing Clinical Project Management Strategic Communications
Regulatory Writing Clinical Project Management Strategic Communications FLEXIBLE. STRATEGIC. INFORMED. COMPLIANT. For over 15 years, Niche Science and Technology has been providing outstanding medical
More informationDomain #1: Analytic Assessment Skills
Domain #1: Analytic Assessment Skills 1. Defines a problem 2. Determines appropriate uses and limitations of both quantitative and qualitative data 3. Selects and defines variables relevant to defined
More information2013/14 Choice Framework
2013/14 Choice Framework April 2013 2013/14 Choice Framework Prepared by the Department of Health April 2013 Contents My NHS care: what choices do I have?... 2 Choosing your care and treatment... 3 Choosing
More informationSouth Australian Women s Health Policy
South Australian Women s Health Policy 1 2 South Australian Women s Health Policy To order copies of this publication, please contact: Department of Health PO Box 287 Rundle Mall Adelaide SA 5000 Telephone:
More informationHarnessing vital data to inform an optimal market access strategy in the UK
White paper Harnessing vital data to inform an optimal market access strategy in the UK The power of the outcomes audit Access to >61M patient lives via EHRs since 2004 Paul Sutton, BA Hons, MA (Oxon),
More informationSubdomain Weight (%)
CLINICAL NURSE LEADER (CNL ) CERTIFICATION EXAM BLUEPRINT SUBDOMAIN WEIGHTS (Effective June 2014) Subdomain Weight (%) Nursing Leadership Horizontal Leadership 7 Interdisciplinary Communication and Collaboration
More informationFrequently Asked Questions regarding European Innovation Partnerships
May 2012 Frequently Asked Questions regarding European Innovation Partnerships 6 December 2010 FAQs 1. What are the objectives behind European innovation partnerships? 2. What concrete benefits can be
More informationResearch Agenda for General Practice / Family Medicine and Primary Health Care in Europe Summary EGPRN
Research Agenda for General Practice / Family Medicine and Primary Health Care in Europe Summary EGPRN EUROPEAN GENERAL PRACTICE RESEARCH NETWO RK EGPRN is a network organisation within WONCA Region Europe
More informationEPF Position Statement on the European Commission s proposal for a Regulation on In Vitro Medical Devices
EPF Position Statement on the European Commission s proposal for a Regulation on In Vitro Medical 03/09/2013 In Vitro Diagnostic medical devices include all tests performed to provide a diagnosis by assessing
More informationTreatment of Chronic Pain: Our Approach
Treatment of Chronic Pain: Our Approach Today s webinar was coordinated by the National Association of Community Health Centers, a partner with the SAMHSA-HRSA Center for Integrated Health Solutions SAMHSA
More informationPharmacy Interchange. The EHR and Pharmacy Integration: A Preferred Future. Benjamin M. Bluml, R.Ph. Vice President, Research APhA Foundation
Pharmacy Interchange The EHR and Pharmacy Integration: A Preferred Future Benjamin M. Bluml, R.Ph. Vice President, Research APhA Foundation Quality Health Care Empowers patients Includes the environment
More informationMedication Therapy Management (MTM) Program
Medication Therapy Management (MTM) Program Regence offers a Medication Therapy Management (MTM) program to ensure you are receiving the most effective medications, while also helping to reduce the risk
More informationClinical trials: The EU perspective. Dr Karim Berkouk, Deputy Head of Unit DG for Research and Innovation Health Directorate European Commission
Clinical trials: The EU perspective Dr Karim Berkouk, Deputy Head of Unit DG for Research and Innovation Health Directorate European Commission Content 1.EU: The global picture 2.EU & Clinial trials: The
More informationKeeping patients safe when they transfer between care providers getting the medicines right
PART 1 Keeping patients safe when they transfer between care providers getting the medicines right Good practice guidance for healthcare professions July 2011 Endorsed by: Foreword Taking a medicine is
More informationELECTRONIC HEALTH RECORDS FOR CLINICAL RESEARCH
ELECTRONIC HEALTH RECORDS FOR CLINICAL RESEARCH! BioMedBridges Annual General Meeting! Dipak Kalra, EuroRec Christian Ohmann, ECRIN Electronic Health Records for Clinical Research! on behalf of the EHR4CR
More informationThe Way Forward: Strategic clinical networks
The Way Forward: Strategic clinical networks The Way Forward Strategic clinical networks First published: 26 July 2012 Prepared by NHS Commissioning Board, a special health authority Contents Foreword...
More informationArthritis Pain Management after Merck s Withdrawal of Vioxx Survey Results
Arthritis Pain Management after Merck s Withdrawal of Vioxx/Survey Results MedicineNet Health Research Survey Report Arthritis Pain Management after Merck s Withdrawal of Vioxx Survey Results Prepared
More informationPIPC: Hepatitis Roundtable Summary and Recommendations on Dissemination and Implementation of Clinical Evidence
PIPC: Hepatitis Roundtable Summary and Recommendations on Dissemination and Implementation of Clinical Evidence On May 8, 2014, the Partnership to Improve Patient Care (PIPC) convened a Roundtable of experts
More informationGreat Expectations: Why Pharma Companies Can t Ignore Patient Services
Accenture Life Sciences Rethink Reshape Restructure... for better patient outcomes Great Expectations: Why Pharma Companies Can t Ignore Patient Services Accenture Research Note: Key findings from a survey
More information